ATE324906T1 - Verwendung von chimäres il6-il6r in huntingtonskrankheit - Google Patents

Verwendung von chimäres il6-il6r in huntingtonskrankheit

Info

Publication number
ATE324906T1
ATE324906T1 AT01972039T AT01972039T ATE324906T1 AT E324906 T1 ATE324906 T1 AT E324906T1 AT 01972039 T AT01972039 T AT 01972039T AT 01972039 T AT01972039 T AT 01972039T AT E324906 T1 ATE324906 T1 AT E324906T1
Authority
AT
Austria
Prior art keywords
huntington
disease
il6r
chimeric
derivative
Prior art date
Application number
AT01972039T
Other languages
English (en)
Inventor
Nicole Deglon
Patrick Aebischer
Jean-Charles Bensadoun
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Application granted granted Critical
Publication of ATE324906T1 publication Critical patent/ATE324906T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01972039T 2000-09-14 2001-09-10 Verwendung von chimäres il6-il6r in huntingtonskrankheit ATE324906T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00120045 2000-09-14

Publications (1)

Publication Number Publication Date
ATE324906T1 true ATE324906T1 (de) 2006-06-15

Family

ID=8169836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01972039T ATE324906T1 (de) 2000-09-14 2001-09-10 Verwendung von chimäres il6-il6r in huntingtonskrankheit

Country Status (13)

Country Link
US (3) US20040057928A1 (de)
EP (1) EP1317273B1 (de)
JP (1) JP5030364B2 (de)
AT (1) ATE324906T1 (de)
AU (2) AU2001291849B2 (de)
CA (1) CA2419954C (de)
CY (1) CY1105116T1 (de)
DE (1) DE60119347T2 (de)
DK (1) DK1317273T3 (de)
ES (1) ES2262680T3 (de)
IL (2) IL154777A0 (de)
PT (1) PT1317273E (de)
WO (1) WO2002022149A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
AU2003275846A1 (en) * 2002-10-24 2004-05-13 The University Of British Columbia Methods for neuroprotection
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004111210A1 (en) * 2003-06-12 2004-12-23 Yeda Research & Development Co.Ltd Enhancement of oligodendrocyte differentiation
WO2005035564A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
EP3401402B1 (de) 2012-06-08 2020-10-14 Alkermes Pharma Ireland Limited Durch zirkuläre permutaton modifizierte liganden als agonisten und antagonisten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
IL99803A (en) * 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
US5792900A (en) * 1991-10-21 1998-08-11 The Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
EP1895010B1 (de) * 1997-12-22 2011-10-12 Oxford Biomedica (UK) Limited Auf dem Virus der infektiösen Pferdeanämie (EIAV) basierende Vektoren
JP4859153B2 (ja) * 1999-02-25 2012-01-25 東ソー株式会社 新規神経系細胞分化促進剤
IL130586A0 (en) * 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases

Also Published As

Publication number Publication date
DK1317273T3 (da) 2006-09-04
CA2419954A1 (en) 2002-03-21
US20100166703A1 (en) 2010-07-01
US8329654B2 (en) 2012-12-11
CY1105116T1 (el) 2009-11-04
PT1317273E (pt) 2006-09-29
AU2001291849B2 (en) 2005-11-24
US20070172454A1 (en) 2007-07-26
US20040057928A1 (en) 2004-03-25
ES2262680T3 (es) 2006-12-01
CA2419954C (en) 2012-01-03
EP1317273A1 (de) 2003-06-11
IL154777A (en) 2010-11-30
EP1317273B1 (de) 2006-05-03
IL154777A0 (en) 2003-10-31
DE60119347D1 (de) 2006-06-08
AU9184901A (en) 2002-03-26
JP5030364B2 (ja) 2012-09-19
JP2004508409A (ja) 2004-03-18
DE60119347T2 (de) 2007-02-22
WO2002022149A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
HK1077518A1 (en) Peptides that modulate nerve growth factor (ngf) activity, their compositions and use
ATE396199T1 (de) Antimikrobielles polypeptid
DOP2002000429A (es) Imidazotriazinas
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE69427650D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
RS51737B (sr) Korišćenje inhibitora il-18
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
BRPI0414215A (pt) tienopirazóis
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
ATE363531T1 (de) Claudin polypeptide
DE60228878D1 (de) Proteine mit il-6 inhibitorischer wirkung
CY1105116T1 (el) Χρηση των il-6r/il-6 χιμαιρων στη νοσο του huntington
DK1228097T3 (da) Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge
SE0102147D0 (sv) New methods
BR0012291A (pt) Fenoxifluorpirimidinas
DK1331940T3 (da) Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2
DK1185293T3 (da) IL6RIL6-kimær til behandling af neurodegenerative sygdomme
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
DK1012286T3 (da) Allelvariant af humant STAT3
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
UA94022C2 (ru) Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1317273

Country of ref document: EP